actr2a Antibody

What is ACVR2A and why is it important in research?

ACVR2A (Activin Receptor Type IIA) is a membrane-localized protein that functions in regulating cell differentiation and other biological processes. The human version comprises 513 amino acid residues with a molecular weight of approximately 57.8 kDa, though researchers should note that two isoforms have been identified. ACVR2A is widely expressed across various tissue types and is also known by alternative names including ACTRII . Its significance in research stems from its critical roles in cellular signaling pathways that regulate differentiation, proliferation, and developmental processes, making it a valuable target for studies in embryogenesis, tissue homeostasis, and pathological conditions including certain cancer types.

How do I distinguish between ACVR2A and related receptor proteins in my experiments?

Distinguishing ACVR2A from related receptors requires careful antibody selection and validation. While ACVR2A shares structural similarities with other TGF-β superfamily receptors, it possesses unique epitope regions that can be targeted for specific detection. When selecting antibodies, researchers should prioritize those raised against unique regions of ACVR2A and validated for minimal cross-reactivity with related proteins like ACVR2B or ACVR1. Verification of specificity can be performed through comparative Western blot analysis of tissues known to express different receptor profiles or through knockout/knockdown validation approaches. Particularly reliable is the use of ACVR2A-knockout cells as negative controls to confirm antibody specificity in your experimental system . Additionally, performing peptide competition assays can further validate specificity by demonstrating signal reduction when antibodies are pre-incubated with the immunizing peptide.

What criteria should I consider when selecting an ACVR2A antibody for my research?

When selecting an ACVR2A antibody, researchers should consider several key factors to ensure optimal experimental outcomes. First, determine the specific application requirements (Western blot, ELISA, IHC, etc.) as antibodies perform differently across applications. For instance, some antibodies like the rabbit polyclonal ACVR2A antibody ab262900 are specifically validated for IHC-P applications with human samples . Second, evaluate species reactivity—verify that the antibody recognizes ACVR2A from your species of interest, as epitope conservation varies across species. Third, consider antibody format (monoclonal vs. polyclonal)—monoclonals typically offer higher specificity while polyclonals provide broader epitope recognition. Fourth, assess the immunogen used for antibody production, preferring antibodies raised against recombinant fragments that represent functional domains of interest . Finally, validate published specificity data and seek antibodies with knockout/knockdown validation, which represents the gold standard for specificity confirmation.

How can I rigorously validate an ACVR2A antibody before incorporating it into my research?

Rigorous validation of ACVR2A antibodies requires a multi-faceted approach to ensure specificity and reliability. Begin with Western blot analysis using positive control lysates from tissues or cell lines known to express ACVR2A (expecting a band at approximately 57.8 kDa) alongside negative controls such as ACVR2A-knockout cells . For immunohistochemistry applications, compare staining patterns with published literature and verify membrane localization consistent with ACVR2A's known cellular distribution . Perform peptide competition assays where pre-incubation of the antibody with its immunizing peptide should abolish or significantly reduce signal. If resources permit, validate across multiple detection methods—concordant results across Western blot, immunofluorescence, and immunoprecipitation provide stronger evidence of specificity. Finally, consider orthogonal validation by correlating protein detection with mRNA expression data from qPCR or RNA-seq experiments. This comprehensive validation approach minimizes the risk of experimental artifacts and ensures reliable ACVR2A detection.

What are the optimal conditions for detecting ACVR2A using Western blot analysis?

Optimizing Western blot detection of ACVR2A requires careful attention to several technical parameters. Sample preparation should begin with efficient membrane protein extraction using detergent-based lysis buffers containing protease inhibitors to preserve ACVR2A integrity. For SDS-PAGE separation, 8-10% gels are recommended to optimally resolve the 57.8 kDa ACVR2A protein . When transferring to PVDF membranes, employ standard wet transfer protocols with methanol-containing buffer to facilitate membrane protein transfer. For blocking, 5% BSA in TBST has been demonstrated to yield superior results compared to milk-based blocking buffers . Primary antibody incubation should be performed overnight at 4°C with ACVR2A antibody at dilutions typically ranging from 1:500-1:2000, depending on the specific antibody. Following thorough washing with TBST (at least three times for 5-10 minutes each), apply appropriate secondary antibodies conjugated to HRP or fluorescent tags (such as Dylight 680) . For densitometry quantification, normalize ACVR2A signal to appropriate housekeeping controls like GAPDH and use software such as ImageJ for analysis, as implemented in published protocols .

How can I optimize immunohistochemical detection of ACVR2A in tissue sections?

Optimizing immunohistochemical detection of ACVR2A in tissue sections requires careful protocol refinement. Begin with proper tissue fixation—4% paraformaldehyde or 10% neutral buffered formalin typically preserves ACVR2A epitopes while maintaining tissue architecture. For paraffin-embedded sections, heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) is crucial to unmask ACVR2A epitopes that may be cross-linked during fixation. Consider using validated antibodies specifically tested for IHC-P applications, such as the rabbit polyclonal ACVR2A antibody referenced in search result . Blocking endogenous peroxidase activity with hydrogen peroxide pre-treatment and implementing a thorough blocking step using 5-10% normal serum corresponding to the secondary antibody species reduces background staining. Primary antibody incubation should be optimized through dilution series testing, typically starting at manufacturer-recommended dilutions, with overnight incubation at 4°C. Detection systems employing polymer-HRP conjugates often provide superior sensitivity compared to traditional ABC methods. Finally, counterstain nuclei appropriately (e.g., hematoxylin) to facilitate visualization of ACVR2A's membrane localization pattern without obscuring specific staining.

How can I address weak or absent ACVR2A signal in Western blot experiments?

Addressing weak or absent ACVR2A signal in Western blot experiments requires systematic troubleshooting across multiple experimental parameters. First, verify ACVR2A expression in your sample—consider using positive control lysates from cells known to express ACVR2A or tissues with documented expression. If expression is confirmed, optimize protein extraction by employing membrane protein enrichment methods, as ACVR2A's membrane localization may require specialized extraction buffers containing appropriate detergents like NP-40 or Triton X-100. Increase protein loading (50-100 μg total protein) to enhance detection sensitivity, particularly for low-abundance expression. For antibody incubation, extend primary antibody incubation times (overnight at 4°C) and consider increasing antibody concentration while monitoring for increased background. Implement signal enhancement strategies such as using high-sensitivity ECL substrates or fluorescent-labeled secondary antibodies with infrared detection systems as described in the literature . Ensure complete protein transfer by evaluating membranes post-transfer using reversible protein stains. If these optimizations fail, consider alternative antibodies targeting different ACVR2A epitopes, as protein modifications or isoform expression may affect epitope accessibility in your specific samples.

What strategies can address non-specific binding or high background when using ACVR2A antibodies?

Addressing non-specific binding and high background with ACVR2A antibodies requires targeted optimization strategies. Start by evaluating blocking conditions—compare 5% BSA in TBST versus 5% non-fat milk to identify optimal blocking for your specific antibody. Increase the stringency of washing steps by extending wash durations (4-5 washes of 10 minutes each) and incorporating higher detergent concentrations (0.1-0.2% Tween-20) in wash buffers. Titrate primary antibody concentrations by performing dilution series experiments to identify the optimal concentration that maximizes specific signal while minimizing background. Pre-adsorb primary antibodies with relevant tissues or cell lysates lacking ACVR2A expression to remove potentially cross-reactive antibodies. For immunohistochemistry applications, implement additional blocking steps targeting endogenous biotin or avidin if using biotin-based detection systems. Consider using monoclonal antibodies which typically exhibit higher specificity than polyclonal alternatives, particularly when non-specific binding persists despite optimization. Finally, validate specificity through knockout/knockdown controls to definitively distinguish between specific and non-specific signals in your experimental system.

How can I use ACVR2A antibodies to investigate protein-protein interactions in signaling pathways?

Investigating ACVR2A protein-protein interactions requires sophisticated biochemical approaches centered around properly validated antibodies. Co-immunoprecipitation (Co-IP) represents the primary method, where ACVR2A antibodies immobilized on protein A/G beads can capture ACVR2A along with its interacting partners from cell lysates. For optimal results, use mild lysis conditions (1% NP-40 or 0.5% Triton X-100) to preserve native protein complexes, and supplement buffers with phosphatase inhibitors to maintain interaction-critical phosphorylation states. Proximity ligation assays (PLA) offer an alternative in situ approach, allowing visualization of ACVR2A interactions within cells by combining ACVR2A antibodies with antibodies against suspected interaction partners, generating fluorescent signals only when proteins are in close proximity (<40 nm). For mapping interaction domains, implement peptide array approaches where ACVR2A-derived peptides are probed with potential binding partners. Advanced researchers might consider bimolecular fluorescence complementation (BiFC), where fragments of fluorescent proteins are fused to ACVR2A and potential partners, generating fluorescence upon interaction. Cross-validation across multiple techniques strengthens interaction claims, as each method presents distinct advantages and limitations for detecting ACVR2A signaling complexes.

How can ACVR2A antibodies be used to study its role in cellular migration and invasion?

ACVR2A antibodies can be instrumental in elucidating this receptor's role in cellular migration and invasion through multiple experimental approaches. Wound healing assays, as described in published protocols , can assess migration capabilities by comparing scratch closure rates between wild-type and ACVR2A-knockout cell populations, with antibodies used to confirm knockout efficiency through Western blotting. Transwell migration and invasion assays provide quantitative measurements of ACVR2A's influence on directed cell movement, particularly when combined with immunofluorescence staining to correlate ACVR2A expression patterns with migratory behavior at the single-cell level. For mechanistic insights, researchers can employ ACVR2A antibodies in immunoprecipitation followed by mass spectrometry to identify migration-related binding partners specifically associated with ACVR2A during migration. Live-cell imaging combined with immunofluorescence allows visualization of ACVR2A redistribution during migration, potentially identifying polarized localization at leading edges or invadopodia structures. Finally, ACVR2A antibodies can be used to track downstream signaling pathway activation (such as TCF7/c-JUN pathways ) through phospho-specific Western blotting or immunofluorescence, connecting receptor engagement to the molecular machinery driving migration and invasion processes.

What considerations are important when using ACVR2A antibodies for quantitative protein analysis?

Quantitative protein analysis of ACVR2A requires rigorous methodological considerations to ensure accuracy and reproducibility. For Western blot-based quantification, researchers must operate within the linear dynamic range of detection—perform standard curve analyses with serial dilutions of positive control samples to establish this range for your specific ACVR2A antibody and detection system. Appropriate normalization strategies are crucial; while GAPDH normalization is commonly used , researchers should verify stable expression of housekeeping proteins across experimental conditions or consider total protein normalization via stain-free technology or Ponceau S as alternatives. For ELISA-based quantification, develop standard curves using recombinant ACVR2A protein and implement spike-recovery experiments to account for matrix effects within your sample type. When analyzing protein expression across different tissues or cell types, validate antibody performance in each specific context, as matrix components may differentially impact antibody binding kinetics. For studies examining ACVR2A expression changes in response to treatments, implement time-course analyses rather than single time points to capture the complete dynamic profile. Finally, employ appropriate statistical analyses for quantitative comparisons—parametric tests require validation of normal distribution, while non-parametric alternatives may be necessary for smaller sample sizes or when normality cannot be confirmed.

How can I effectively use ACVR2A antibodies in functional blocking experiments?

Implementing ACVR2A functional blocking experiments requires careful selection of antibodies with validated neutralizing activity. Begin by selecting antibodies raised against the extracellular domain of ACVR2A that are specifically characterized for blocking function, rather than just detection applications. Prior to cell-based assays, verify blocking efficacy through in vitro binding inhibition assays that measure disruption of ACVR2A interaction with its ligands (such as Activin A). For cell culture applications, optimize antibody concentration through dose-response experiments, typically starting at 1-10 μg/mL with appropriate isotype controls to distinguish specific from non-specific effects. Consider the timing of antibody addition relative to ligand exposure—pre-incubation of cells with blocking antibodies (30-60 minutes) before ligand addition often yields optimal inhibition. Validate functional blocking through downstream readouts such as SMAD2/3 phosphorylation status via Western blotting or reporter gene assays containing SMAD-responsive elements. For extended experiments, determine antibody stability in culture conditions and implement replenishment schedules accordingly. Finally, complement antibody blocking with genetic approaches (siRNA, CRISPR-Cas9) targeting ACVR2A to corroborate that observed effects are specifically mediated through ACVR2A inhibition rather than off-target antibody interactions.

What approaches can be used to study ACVR2A-mediated gene expression changes?

Studying ACVR2A-mediated gene expression changes requires integrating antibody-based protein detection with transcriptomic analysis techniques. A comprehensive approach begins with establishing ACVR2A-knockout or knockdown models with knockout validation using ACVR2A antibodies in Western blot analysis . RNA-sequencing analysis comparing wild-type and ACVR2A-deficient cells can identify differentially expressed genes (DEGs) regulated by ACVR2A signaling. Published protocols recommend using DESeq2 R package (version 1.10.1) for differential expression analysis with stringent statistical parameters (adjusted p-value < 0.05, |log2(fold change)| ≥ 1) . For pathway analysis, KOBAS (version 3.0) software has been successfully employed to analyze DEGs within KEGG pathways . These transcriptomic findings should be validated through qRT-PCR for selected genes and extended to protein-level confirmation using antibody-based approaches like Western blot or immunohistochemistry. Chromatin immunoprecipitation (ChIP) using antibodies against transcription factors downstream of ACVR2A (such as TCF7/c-JUN as identified in recent research ) can elucidate direct transcriptional regulation mechanisms. Finally, rescue experiments reintroducing wild-type ACVR2A into knockout models with subsequent gene expression analysis provides powerful confirmation of ACVR2A-specific regulatory effects, completing a rigorous analysis of ACVR2A's role in transcriptional regulation.

How are ACVR2A antibodies being utilized in the study of cell differentiation mechanisms?

The application of ACVR2A antibodies in cell differentiation research spans multiple developmental and regenerative biology contexts. Recent methodological innovations include the use of phospho-specific ACVR2A antibodies to track receptor activation status during critical differentiation transitions, providing temporal resolution of signaling events. Researchers are implementing dual immunofluorescence approaches combining ACVR2A antibodies with lineage-specific markers to correlate receptor expression with developmental fate decisions at the single-cell level. With ACVR2A's established role in regulating cell differentiation , antibody-mediated receptor tracking in live-cell imaging now allows visualization of receptor dynamics during differentiation processes. Advanced functional studies utilize ACVR2A antibodies to isolate receptor-containing signaling complexes at different differentiation stages, followed by mass spectrometry to identify stage-specific interaction partners that may regulate lineage commitment. This approach has been particularly valuable in stem cell biology, where ACVR2A signaling influences pluripotency maintenance versus differentiation decisions. Additionally, researchers are employing ACVR2A antibodies in developmental tissue sections to map expression patterns across embryogenesis, creating comprehensive atlases of receptor distribution that correlate with morphogenic events and providing crucial spatial context for functional studies of ACVR2A in differentiation processes.

What role do ACVR2A antibodies play in investigating trophoblast cell invasion mechanisms?

ACVR2A antibodies are instrumental in unraveling the molecular mechanisms governing trophoblast invasion, a critical process in placental development and pregnancy establishment. Recent research has identified ACVR2A as a facilitator of trophoblast cell invasion through TCF7/c-JUN signaling pathways , with antibody-based detection methods playing a central role in these discoveries. Methodologically, ACVR2A antibodies enable comparative protein expression analysis between invasive and non-invasive trophoblast populations through Western blotting and immunohistochemistry. Wound healing assays combined with ACVR2A immunodetection have established correlations between receptor expression and migratory capacity in trophoblast models . For mechanistic investigations, co-immunoprecipitation with ACVR2A antibodies followed by mass spectrometry has identified novel interaction partners specific to invasive trophoblast phenotypes. Researchers have implemented ACVR2A knockdown models validated by antibody detection to directly assess functional requirements in invasion processes, with proliferation monitored through complementary CCK-8 assays . Advanced trophoblast-decidual co-culture models with immunofluorescent ACVR2A detection are now being employed to study receptor distribution during heterotypic cell interactions that regulate invasion depth. These multifaceted approaches utilizing ACVR2A antibodies have collectively established this receptor as a key regulator of trophoblast function, with potential implications for understanding pregnancy disorders characterized by aberrant placentation.

What modifications to standard protocols are needed when using ACVR2A antibodies in flow cytometry?

Adapting ACVR2A antibody protocols for flow cytometry applications requires specific technical modifications to optimize detection of this membrane-localized receptor . Cell preparation demands particular attention—use gentle enzymatic dissociation methods (Accutase rather than trypsin) to preserve the extracellular domain of ACVR2A that contains most detectable epitopes. For fixation, 2-4% paraformaldehyde is recommended, avoiding methanol-based fixatives that may disrupt membrane protein epitopes. Permeabilization should be mild if intracellular domains are targeted (0.1% saponin or 0.1% Triton X-100), while remaining optional when targeting extracellular domains. Blocking with 2-5% serum from the secondary antibody species supplemented with 1% BSA effectively reduces non-specific binding. Primary ACVR2A antibody concentrations typically require 2-5 fold higher concentrations than used for Western blotting, necessitating titration experiments to identify optimal signal-to-noise ratios. For multicolor panels, select fluorophores with minimal spectral overlap with other markers in your panel, considering brightness requirements for this moderately expressed receptor. Include proper controls: FMO (fluorescence minus one), isotype controls, and when possible, ACVR2A-knockout cells as negative controls. Finally, implement live/dead discrimination dyes to exclude non-viable cells that may exhibit artificial antibody binding, ensuring accurate quantification of ACVR2A-positive populations.